New drug duo tested for Tough-to-Treat stomach cancers
NCT ID NCT05041153
Summary
This early-stage study is testing whether combining two existing drugs, pembrolizumab and lenvatinib, can help control advanced stomach or gastroesophageal cancers that have spread or cannot be surgically removed. The trial is for adults whose cancer has continued to grow despite receiving standard treatments. Researchers aim to see if this combination can shrink tumors and control the disease for longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.